Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement regimen or making changes to your health routine. The information presented here is based on published research but should not replace professional medical guidance.
What Is Quercetin?
Quercetin is a plant-derived flavonoid found in onions, capers, apples, kale, and green tea. It’s one of the most abundant dietary polyphenols consumed in a typical Western diet, with average intake estimated at between 10 and 100 mg per day from food sources alone. As a quercetin supplement, however, doses used in clinical trials reach far beyond what any realistic diet provides — often 500 mg to 2,000 mg daily, and sometimes in short, pulsed “senolytic” protocols rather than continuous supplementation.
I’ve been tracking quercetin research for well over a decade. It first attracted serious scientific attention as an antioxidant and anti-inflammatory compound. But in the past ten years, interest has shifted considerably towards its potential as a senolytic agent — a compound capable of selectively clearing senescent cells, which are increasingly recognised as a key driver of biological ageing. If that term is new to you, I’d recommend reading my overview of the hallmarks of ageing first, as cellular senescence sits prominently among them.
Quercetin is not a magic bullet. But it is one of the more interesting and reasonably well-studied compounds in the longevity toolkit — particularly when the human evidence is evaluated carefully rather than extrapolated uncritically from mouse studies.
Mechanism of Action: How Quercetin Works at the Cellular Level
Understanding why quercetin might benefit ageing biology requires looking at several distinct mechanisms, because this compound operates on multiple pathways simultaneously.
Senolytic Activity: Disrupting the SASP Survival Network
Senescent cells — those that have permanently exited the cell cycle following DNA damage, telomere erosion, or oncogenic stress — are not inert bystanders. They secrete a cocktail of pro-inflammatory cytokines, chemokines, matrix metalloproteinases, and growth factors collectively known as the Senescence-Associated Secretory Phenotype, or SASP. This chronic low-grade inflammatory milieu damages surrounding tissue and accelerates dysfunction in neighbouring cells.
Critically, senescent cells resist apoptosis (programmed cell death) by upregulating pro-survival pathways. Research from the Mayo Clinic group led by James Kirkland identified that quercetin, particularly in combination with the drug dasatinib, disrupts these pro-survival networks — specifically the PI3K/AKT pathway, BCL-2 family anti-apoptotic proteins, and the p53/p21 axis. By transiently inhibiting these survival signals, quercetin essentially tips the balance back towards apoptosis in senescent cells whilst leaving non-senescent cells relatively unaffected. This selectivity — theoretical at the doses tested — is what makes senolytics conceptually distinct from broad cytotoxic agents.
Anti-Inflammatory Mechanisms
Quercetin inhibits NF-κB signalling, a master transcription factor driving inflammatory gene expression. It also suppresses NLRP3 inflammasome activation, reduces prostaglandin synthesis by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), and downregulates the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. These effects are well-documented in cell culture and animal studies, and there is some human evidence supporting reductions in circulating inflammatory markers.
Antioxidant and Metal-Chelating Activity
Quercetin’s polyphenolic structure allows it to directly scavenge free radicals and chelate redox-active metal ions such as iron and copper, thereby interrupting Fenton reactions that generate hydroxyl radicals. It also upregulates endogenous antioxidant defence through the Nrf2/ARE pathway, increasing expression of haem oxygenase-1 (HO-1), glutathione peroxidase, and superoxide dismutase.
mTOR and Autophagy Modulation
There is emerging evidence that quercetin can modulate mTORC1 signalling — a nutrient-sensing kinase complex central to ageing biology — and promote autophagy, the cellular “self-cleaning” process that declines with age. The interaction here is nuanced and dose-dependent; at this point I would not overstate this mechanism in the absence of robust human data.
Senolytic Evidence: What the Research Actually Shows
Let me be direct about where the evidence stands, because this is an area where enthusiasm frequently outruns the data.
The Preclinical Foundation Is Genuinely Compelling
The landmark 2015 study by Zhu and colleagues at Mayo Clinic (PMID: 26646499) demonstrated that dasatinib plus quercetin (D+Q) selectively eliminated senescent cells in aged mice, improving physical function, reducing frailty, and extending healthspan. These were striking results. A 2017 follow-up (PMID: 28479154) showed that short pulsed treatment with D+Q in mice transplanted with senescent cells was sufficient to improve physical function and extend remaining lifespan — even when treatment began late in life. This “pulsed” dosing concept is important and has been carried into human trial design.
Translation to Humans Is Partial
Here is where I must be honest: the mouse-to-human translation is not complete. Quercetin metabolism, bioavailability, and tissue distribution differ substantially between rodents and humans. Rodents also have much shorter telomeres and a compressed senescent cell accumulation timeline compared to humans. That said, we now have initial human data, which I’ll cover in the next section.
Human Trial Evidence
Human trial data on quercetin as a senolytic remains in early stages, but it is real and growing.
The Idiopathic Pulmonary Fibrosis Study
The first-in-human senolytic trial was published by Justice and colleagues in 2019 (PMID: 30974999). Fourteen patients with idiopathic pulmonary fibrosis (IPF) — a condition associated with high senescent cell burden — received three weeks of D+Q treatment (dasatinib 100 mg/day plus quercetin 1,000 mg/day for three consecutive days per week). The results showed reductions in senescence-associated biomarkers including p16, p21, and SASP factors in adipose tissue, skin, and blood. Physical function also improved modestly. This was an open-label pilot without a placebo arm, so the results must be interpreted cautiously. But it provided proof-of-concept that the D+Q combination can reduce senescent cell markers in living humans.
Diabetic Kidney Disease
A 2019 pilot clinical trial by Hickson and colleagues (PMID: 30779849) enrolled nine patients with diabetic kidney disease — again a condition with known elevated senescent cell burden — using the same D+Q pulsed protocol. They observed reductions in circulating SASP factors and senescent cell markers. Small sample, no placebo control, but consistent with mechanistic predictions.
Quercetin Alone: Anti-Inflammatory and Cardiometabolic Evidence
Setting aside the D+Q senolytic work, there is a body of randomised controlled trial (RCT) evidence for quercetin supplementation alone on inflammatory and cardiometabolic markers. A meta-analysis by Serban and colleagues (PMID: 26781581) pooled seven RCTs and found that quercetin supplementation significantly reduced systolic blood pressure (mean reduction approximately 3.04 mmHg) and diastolic blood pressure (approximately 2.63 mmHg). A separate meta-analysis (PMID: 23368931) found significant reductions in C-reactive protein (CRP) and tumour necrosis factor-alpha with quercetin supplementation, though effect sizes were modest.
Exercise Performance and Endurance
A meta-analysis by Kressler and colleagues (PMID: 21226679) found a small but statistically significant improvement in VO2 max with quercetin supplementation — approximately 0.2 ml/kg/min on average across 11 studies. Clinically modest, but consistent with the compound’s mitochondrial biogenesis effects via PGC-1α upregulation.
Quercetin and Fisetin: The Senolytic Stack
Quercetin is frequently discussed alongside fisetin, another flavonoid that has attracted significant senolytic interest. They are often grouped together because both were identified in the same landmark 2018 National Institute on Aging-funded screen of 10 flavonoids for senolytic activity (Yousefzadeh et al., PMID: 30279143). In that study, fisetin outperformed quercetin on some metrics of senolytic potency in mouse models — reducing senescent cell burden by up to 50% in aged mice, improving healthspan markers, and even modestly extending median and maximum lifespan.
Does this mean fisetin is “better” than quercetin? Not necessarily — they work through overlapping but distinct mechanisms, and combination approaches are currently being investigated in clinical trials (notably the SToMP-AD trial looking at D+Q in Alzheimer’s disease prevention). In supplement form, some longevity-focused individuals take quercetin and fisetin together in periodic pulsed protocols, typically two to three consecutive days per month. I regard this approach as biologically plausible but not yet validated in humans as a combination. The absence of harm data for long-term combined use is also something I take seriously.
Dosage Guidance
Dosage for quercetin supplementation depends considerably on what you’re trying to achieve. There is no universally agreed human longevity dose — this must be stated clearly.
For General Anti-Inflammatory and Cardiometabolic Benefits
The RCT literature supporting blood pressure and CRP reductions used doses typically ranging from 150 mg to 1,000 mg per day, taken continuously. The most commonly studied dose in these trials is 500 mg twice daily. Based on the available data, this is a reasonable starting point for someone seeking general anti-inflammatory support.
For Senolytic Protocols (Pulsed Dosing)
The human senolytic trials used 1,000 mg of quercetin per day for three consecutive days, repeated weekly for three weeks (in the IPF study). Independent researchers and longevity clinicians using quercetin-only senolytic approaches often recommend 1,000–2,000 mg per day for two to three consecutive days per month, though I must be clear that this specific protocol has no direct human RCT validation for quercetin alone.
Timing and Food Interactions
Quercetin is fat-soluble and should be taken with a meal containing some fat to maximise absorption. Some studies have shown that combining quercetin with bromelain (a pineapple-derived enzyme) or vitamin C can modestly enhance bioavailability, though the evidence for these combinations is not conclusive.
Forms and Bioavailability: Comparison Table
One of the persistent challenges with quercetin is poor and variable bioavailability. Standard quercetin aglycone (the free form) is estimated to have oral bioavailability of around 1–3% in some assessments, though this figure varies widely depending on the food matrix, gut microbiome composition, and formulation. Several enhanced delivery forms have been developed to address this.
| Form | Relative Bioavailability | Evidence Quality | Typical Cost | Notes |
|---|---|---|---|---|
| Quercetin aglycone (standard) | Low (baseline) | Moderate (most trials use this) | Low | Most commonly used in clinical trials; variable absorption |
| Quercetin glycosides (e.g., rutin, isoquercetin) | Higher than aglycone | Moderate | Moderate | Isoquercetin (quercetin-3-glucoside) shows 3–5× better absorption in some studies |
| Quercetin phytosome (with phosphatidylcholine) | Significantly higher | Limited but promising | Moderate–High | Sophora japonica-derived; some human bioavailability studies show ~20× improvement over standard |
| Quercetin with bromelain | Modestly enhanced | Limited | Low–Moderate | Bromelain may aid intestinal absorption; evidence is weak |
| Quercetin nanoparticle / liposomal | Potentially high | Very limited in humans | High | Promising preclinical data; human bioavailability studies sparse |
| Isoquercetin (enzymatically modified) | High (best-evidenced enhancement) | Moderate | Moderate–High | Used in some DVT prevention trials; fastest intestinal absorption of any quercetin form |
My current view: if cost is a concern, standard quercetin aglycone taken with a fatty meal is a reasonable starting point given that most trial data uses this form. If you are prepared to invest more and prioritise bioavailability, isoquercetin or a quercetin phytosome formulation is worth considering. I’m sceptical of the most dramatic bioavailability claims (the “20× improvement” figures) until they are replicated in larger studies.
Side Effects and Safety
Quercetin has a generally favourable safety profile at doses up to 1,000 mg/day in studies of up to 12 weeks’ duration. Reported adverse effects are typically mild and include headache, tingling sensations in extremities, and gastrointestinal discomfort. A 2010 safety review (PMID: 20614191) examining multiple human trials found no serious adverse events at doses up to 1,000 mg/day.
However, several important caveats exist:
- Drug interactions: As noted above, quercetin inhibits CYP3A4 and CYP2C9 enzymes, which metabolise a wide range of medications. This is a meaningful concern at higher doses.
- Thyroid function: Some research has suggested quercetin may interfere with thyroid peroxidase activity. This is based primarily on in vitro data, but individuals with thyroid conditions should be aware of this and consider discussing it with their doctor.
- Pregnancy and breastfeeding: Insufficient safety data exists; supplementation is not advisable during pregnancy.
- High-dose, long-term use: There is very limited data on safety beyond 12 weeks at doses of 1,000 mg/day or above. Pulsed protocols may help mitigate this uncertainty, but they have their own unknowns.
- Kidney stone risk: Quercetin is partially metabolised to oxalic acid. Individuals prone to calcium oxalate kidney stones should exercise caution at high doses.
Who Should Consider a Quercetin Supplement?
Being honest about who is and is not a good candidate for quercetin supplementation matters to me more than maximising appeal.
Potentially Good Candidates
- Adults aged 45+ with a genuine interest in evidence-based approaches to reducing chronic low-grade inflammation, who understand the limitations of the current evidence.
- Those with elevated inflammatory markers (CRP, IL-6) where dietary and lifestyle interventions have been optimised but inflammation persists.
- Individuals interested in senolytic protocols who are not candidates for or comfortable with dasatinib (a prescription drug), and who accept that quercetin-alone senolytic evidence in humans is preliminary.
- Those with mildly elevated blood pressure (alongside — never instead of — appropriate medical management).
Who Should Be Cautious or Avoid It
- Anyone taking medications metabolised by CYP3A4 or CYP2C9 (including statins, warfarin, cyclosporine, many antibiotics) — drug interactions are a real concern.
- Individuals with hypothyroidism or on thyroid medication.
- Pregnant or breastfeeding women.
- Those with a history of calcium oxalate kidney stones.
- People hoping quercetin will replace established cardiovascular or anti-inflammatory medications — the evidence does not support this.
Honest Verdict
Quercetin sits in an interesting position in the longevity supplement landscape. It has stronger mechanistic rationale than most compounds on the market, a growing body of human trial evidence for anti-inflammatory and cardiometabolic effects, and early but genuinely intriguing human senolytic data (primarily in combination with dasatinib). It is not a compound I dismiss.
That said, I think it is often oversold specifically as a standalone senolytic. The dramatic lifespan-extension results in mouse models were achieved with the D+Q combination — the dasatinib component is doing substantial work there, and quercetin alone appears to be a weaker senolytic than either fisetin or the D+Q combination. The bioavailability problem is real and not fully solved by current enhanced formulations despite marketing claims.
Where I find quercetin most credible is as a broad-spectrum anti-inflammatory and antioxidant compound with a reasonable human evidence base for modest cardiometabolic benefits, and as a potential component of periodic senolytic protocols used alongside fisetin for those who want to explore this approach without using dasatinib. I personally use quercetin phytosome at 500 mg taken with food on a daily basis during periods of known inflammatory stress (intense training blocks, illness recovery), and I use a pulsed higher-dose approach two to three days per month as part of a broader longevity protocol. But I hold that lightly — I’m running an experiment of one, and I don’t present personal use as evidence.
If I were rating quercetin purely on the human longevity evidence currently available, I would call it a “moderate evidence, promising trajectory” supplement — worth serious consideration for the right individual, but not something I would overstate.
Frequently Asked Questions
What does a quercetin supplement actually do?
Quercetin is a flavonoid polyphenol with multiple biological actions: it suppresses chronic inflammation by inhibiting NF-κB signalling and the NLRP3 inflammasome, acts as an antioxidant via free radical scavenging and Nrf2 pathway upregulation, and — at higher doses in pulsed protocols — may act as a senolytic by disrupting the pro-survival signals that allow damaged senescent cells to persist. Human RCT evidence supports modest reductions in blood pressure and inflammatory markers. Senolytic effects in humans have been demonstrated primarily when quercetin is combined with the drug dasatinib, not with quercetin alone.
What is the best quercetin dosage for anti-ageing benefits?
There is no established “anti-ageing dose” validated in long-term human trials. Clinical studies on anti-inflammatory and cardiometabolic effects typically used 500–1,000 mg per day taken continuously. Senolytic protocols — based on the D+Q human trials — used 1,000 mg of quercetin per day for three consecutive days per week over three weeks. Some longevity-focused clinicians recommend 1,000–2,000 mg for two to three consecutive days per month as a pulsed senolytic approach using quercetin alone, but this specific protocol lacks direct human RCT validation. Always take quercetin with food containing fat to maximise absorption.
Should I take quercetin and fisetin together?
Quercetin and fisetin both have senolytic properties, operate via overlapping but distinct mechanisms, and were identified in the same landmark flavonoid screen for senolytic activity. Fisetin showed stronger standalone senolytic effects in mouse models. Many longevity researchers regard them as potentially complementary. However, there are no published human trials testing the quercetin–fisetin combination specifically, so taking them together is an approach based on plausible biology rather than direct human evidence. If you decide to explore this approach, the risk profile appears low, but the benefit is unproven in humans.
Are there any significant drug interactions with quercetin?
Yes — this is an important consideration. Quercetin inhibits cytochrome P450 enzymes CYP3A4 and CYP2C9, which are responsible for metabolising a wide range of commonly prescribed medications including statins, warfarin, cyclosporine, several antibiotics, and many others. Inhibiting these enzymes can increase blood levels of co-administered drugs, potentially causing adverse effects or toxicity. At doses of 500 mg or above — especially at senolytic doses of 1,000 mg or more — these interactions are clinically relevant. Anyone taking prescription medications should discuss quercetin supplementation with their doctor before starting.
Which form of quercetin has the best bioavailability?
Standard quercetin aglycone (the free form found in most supplements) has relatively poor and variable oral bioavailability. Enhanced forms include quercetin glycosides such as isoquercetin (quercetin-3-glucoside), which shows significantly faster and more complete intestinal absorption than the aglycone form. Quercetin phytosome (bound to phosphatidylcholine) is another option with human bioavailability data suggesting improved absorption compared to standard quercetin. Liposomal and nanoparticle formulations show promise but have limited human data. The most evidence-backed enhanced form is currently isoquercetin, which has been used in clinical trials for deep vein thrombosis prevention.
Is quercetin safe to take long-term?
Quercetin has a good safety record in clinical trials up to 12 weeks at doses of 1,000 mg/day, with mild and infrequent adverse effects. However, there is very limited data on continuous use beyond this period at higher doses. The pulsed dosing approach (two to three days per month at higher doses, rather than daily supplementation) is sometimes advocated partly to reduce long-term exposure concerns. Specific populations — including those on CYP450-metabolised medications, those with thyroid conditions, pregnant women, and those prone to kidney stones — should exercise particular caution or avoid supplementation altogether.
Citations
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658. PMID: 26646499
- Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24(8):1246–1256. PMID: 28479154
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554–563. PMID: 30974999
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446–456. PMID: 30779849
- Serban MC, Sahebkar A, Zanchetti A, et al. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2016;5(7):e002713. PMID